Key Points Novo Nordisk stock reported strong sales growth but lowered sales forecasts this morning. The good news: 2025 earnings will grow faster than sales. 10 stocks we like better than Novo Nordisk › GLP-1 drugmaker NovoNordisk's (NYSE: NVO) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning. Novo reported smaller-than-expected Q1 sales and lowered its forecast for the rest of the year. Investors seem more interested in comments about the chances Wegovy sales will improve later this year through the company's partnership with Hims & HersHealth(NYSE: HIMS) as other GLP-1 compounders are driven out of the market.Image source: Getty Images. Novo Nordisk Q1 earnings Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 billion DKK ($11.9 billion). Net income for the quarter rose 14% to 29 billion DKK ($4.4 billion). According to S&P Global Market Intelligence data, that works out to $0.95 per share. The growth rate in Q1 was good, but management lowered its forecast for the rest of this year "due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US." Is Novo Nordisk stock a buy? Management now forecasts sales growth in the 13%-21% range this year. It says operating profits will grow faster at 16%-24%. And of course, Novo Nordisk stock itself currently sells for 19.3 times trailing earnings. At a midpoint expected growth rate of 20%, that seems an attractive valuation, yielding a PEG ratio of just under 1.0. Throw in a tidy 2.4% dividend yield, and the prospect for market share gains through the company's partnership with Hims & Hers, and I continue to see Novo Nordisk as the best value play in GLP-1 weight-loss drugs. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $613,546!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $695,897!* Now, it’s worth notingStock Advisor’s total average return is893% — a market-crushing outperformance compared to162%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » Story Continues *Stock Advisor returns as of May 5, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Popped After Earnings was originally published by The Motley Fool View Comments
Why Novo Nordisk Stock Popped After Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...